Vaccinia Virus Polypeptides for Orthopoxvirus Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Orthopoxvirus infections, such as smallpox, are no longer routinely administered due to the eradication of smallpox, and there is a renewed interest in biodefense countermeasures for potential outbreaks like monkeypox, highlighting the need for effective vaccines that induce a protective immune response.
Innovation Solution
Development of vaccines using naturally processed and HLA-presented vaccinia virus-derived polypeptides, identified through two-dimensional liquid chromatography coupled with mass spectrometry, which can induce a protective therapeutic immune response by targeting specific epitopes recognized by T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional whole-virus vaccines are used, then broad immune coverage is achieved, but safety concerns and reactogenicity increase
Solution Approach 1:
The patent extracts specific protective epitopes from the whole vaccinia virus structure. By identifying and isolating the critical immunogenic regions (such as A27L, A33R, B5R polypeptides) that provide protection against orthopoxviruses, the invention creates refined vaccines containing only these essential protective components, thereby maintaining immune coverage while eliminating unnecessary viral elements that cause reactogenicity.
Solution Approach 2:
The patent segments the vaccinia virus into discrete epitope components. Rather than using the complete virus, the invention divides the viral structure into specific functional units (individual epitopes or small polypeptide fragments) that can be independently characterized and combined, allowing selective inclusion of protective elements while excluding harmful ones.
2Object-affected harmful factors
If epitope-specific vaccines are developed, then safety is improved, but manufacturing complexity increases
Solution Approach 1:
The patent performs preliminary identification and characterization of protective epitopes using advanced mass spectrometry techniques (LC-MS/MS) to map HLA-presented peptides. This preliminary action of precisely identifying which epitopes are naturally processed and presented to T cells provides a clear roadmap for vaccine design, simplifying subsequent manufacturing by focusing production on pre-validated protective components rather than requiring complex screening processes.
Solution Approach 2:
The patent creates simplified copies of the essential viral components. By synthesizing only the critical epitope sequences (rather than producing entire viral particles), the invention manufactures functional vaccine antigens that replicate the protective effect of whole-virus vaccination without requiring complex viral culture and purification systems.
Data Source
AI summary
This document provides methods and materials related to polypeptides present in a vaccinia virus (e.g., polypeptides that can be isolated from naturally processed and presented class I polypeptides originating from vaccinia virus, a member of the Orthopoxvirus family). For example, methods for generating a vaccine comprising one or more of vaccinia virus polypeptides disclosed herein for preventing or treating Orthopoxvirus infection are provided. In addition, kits related to the use of vaccinia polypeptides are provided.